Isolation_NN of_IN Nocardia_NP paucivorans_NNS from_IN the_DT Cerebrospinal_NP Fluid_NP of_IN a_DT Patient_NP with_IN Relapse_NP of_IN Cerebral_NP Nocardiosis_NP Nocardia_NP paucivorans_NNS represents_VBZ a_DT new_JJ species_NN of_IN the_DT genus_NN Nocardia_NN that_WDT has_VBZ recently_RB been_VBN isolated_VBN from_IN bronchial_JJ secretions_NNS of_IN a_DT patient_NN with_IN chronic_JJ lung_NN disease_NN ._SENT Here_RB ,_, we_PP report_VBP on_IN the_DT course_NN of_IN a_DT disseminated_VBN infection_NN caused_VBN by_IN this_DT species_NN :_: i.e._FW ,_, cerebral_JJ and_CC subsequent_JJ meningeal_JJ manifestations_NNS ,_, isolation_NN from_IN the_DT cerebrospinal_JJ fluid_NN ,_, and_CC in_IN vitro_NN susceptibility_NN to_TO various_JJ antimicrobial_JJ agents_NNS ._SENT A_DT 63-year-old_JJ man_NN presented_VBN to_TO the_DT emergency_NN department_NN of_IN this_DT hospital_NN in_IN July_NP 2000_CD with_IN a_DT 10-day_JJ history_NN of_IN headaches_NNS and_CC mild_JJ ataxia_NN on_IN the_DT right-hand_JJ side_NN ._SENT Cranial_JJ computed_VBN tomography_NN showed_VBD a_DT cerebellar_JJ mass_NN with_IN surrounding_VBG edema_NN ,_, without_IN signs_NNS of_IN intracranial_JJ bleeding_NN ,_, and_CC the_DT result_NN was_VBD confirmed_VBN by_IN magnetic_JJ resonance_NN imaging_NN ._SENT The_DT patient_NN 's_POS condition_NN improved_VBN with_IN conservative_JJ treatment_NN ._SENT A_DT few_JJ days_NNS after_IN admission_NN ,_, a_DT blood_NN pressure_NN crisis_NN occurred_VBD ,_, resulting_VBG in_IN an_DT impaired_JJ neurological_JJ status_NN that_WDT persisted_VBD despite_IN prompt_JJ sufficient_JJ control_NN of_IN systemic_JJ blood_NN pressure_NN ._SENT Imaging_NP demonstrated_VBD a_DT minor_JJ perilesional_JJ bleeding_NN in_IN the_DT cerebellum_NN as_RB well_RB as_IN an_DT increase_NN in_IN the_DT size_NN of_IN the_DT original_JJ mass_NN ._SENT The_DT patient_NN underwent_VBD craniotomy_NN ,_, during_IN which_WDT the_DT mass_NN ,_, now_RB identified_VBN as_IN an_DT abscess_NN ,_, was_VBD removed_VBN ._SENT Histological_JJ investigation_NN of_IN the_DT biopsies_NNS yielded_VBD granulomatous_JJ inflammation_NN ._SENT Additionally_RB ,_, infiltration_NN of_IN the_DT tissue_NN by_IN dark_JJ brown_NN to_TO black_JJ branching_NN rods_NNS was_VBD seen_VBN in_IN Grocott-stained_JJ sections_NNS ,_, a_DT typical_JJ feature_NN of_IN nocardiae_NNS ._SENT Brain_NN abscess_NN material_NN was_VBD inoculated_VBN in_IN brain_NN heart_NN broth_NN (_( BHB_NP )_) and_CC blood_NN (_( BA_NP )_) and_CC chocolate_NN (_( CA_NP )_) agars_NNS and_CC incubated_VBN at_IN 36C_JJ in_IN an_DT atmosphere_NN enriched_VBN with_IN 5_CD %_NN CO2_NN ._SENT However_RB ,_, no_DT growth_NN was_VBD found_VBN after_IN 10_CD days_NNS of_IN incubation_NN ._SENT Failure_NN to_TO isolate_VB the_DT pathogen_NN despite_IN its_PP$ histological_JJ demonstration_NN may_MD have_VB been_VBN due_JJ to_TO sampling_VBG error_NN ._SENT A_DT decreased_VBN number_NN of_IN CD4+_NP T_NN cells_NNS (_( 172_CD per_IN mul_NN )_) was_VBD found_VBN ,_, demonstrating_VBG an_DT immunodeficiency_NN of_IN unknown_JJ origin_NN ,_, since_IN human_JJ immunodeficiency_NN virus_NN types_NNS 1_CD and_CC 2_CD antibody_NN and_CC p24_JJ antigen_NN tests_NNS were_VBD negative_JJ ._SENT The_DT patient_NN received_VBD a_DT course_NN of_IN intravenous_JJ trimethoprim-sulfamethoxazole_NN ,_, which_WDT was_VBD replaced_VBN by_IN amikacin_NN plus_CC a_DT carbapenem_NN because_IN of_IN systemic_JJ side_NN effects_NNS ._SENT This_DT therapy_NN was_VBD administered_VBN for_IN 6_CD weeks_NNS ,_, with_IN imipenem_NN given_VBN during_IN the_DT first_JJ week_NN and_CC meropenem_NN ,_, which_WDT was_VBD better_RBR tolerated_VBN ,_, given_VBN during_IN the_DT remaining_VBG 5_CD weeks_NNS ._SENT The_DT patient_NN made_VBD a_DT slow_JJ recovery_NN and_CC was_VBD discharged_VBN with_IN minor_JJ neurological_JJ deficits_NNS (_( tremor_NN and_CC dysdiadochokinesis_NN )_) ._SENT The_DT CD4+_NP T-cell_NN count_NN remained_VBD low_JJ (_( maximum_JJ count_NN ,_, 414_CD per_IN mul_NN )_) ._SENT Treatment_NN of_IN the_DT nocardiosis_NN was_VBD continued_VBN with_IN oral_JJ minocycline_NN ._SENT Antibiotic_JJ therapy_NN was_VBD discontinued_VBN after_IN a_DT duration_NN of_IN 6_CD months_NNS ._SENT The_DT patient_NN developed_VBD headaches_NNS and_CC singultus_NN within_IN 2_CD weeks_NNS ,_, resulting_VBG in_IN readmission_NN to_TO the_DT hospital_NN ._SENT A_DT lumbar_JJ puncture_NN at_IN readmission_NP showed_VBD 1,306_CD granulocytes_NNS per_IN mm3_NN in_IN the_DT cerebrospinal_JJ fluid_NN (_( CSF_NP )_) without_IN detection_NN of_IN infectious_JJ agents_NNS upon_IN microscopy_NN ._SENT Treatment_NN for_IN suspected_JJ bacterial_JJ meningitis_NN was_VBD initiated_VBN with_IN ceftriaxone_NN plus_CC ampicillin_NN ._SENT However_RB ,_, the_DT patient_NN 's_POS condition_NN did_VBD not_RB improve_VB under_IN this_DT regimen_NN ,_, and_CC no_DT fast-growing_JJ bacteria_NNS could_MD be_VB isolated_VBN ._SENT Therefore_RB ,_, therapy_NN was_VBD changed_VBN after_IN 3_CD days_NNS to_TO amikacin_NN plus_CC meropenem_NN ,_, assuming_VBG a_DT meningeal_JJ manifestation_NN of_IN nocardiosis_NN ._SENT The_DT administration_NN of_IN amikacin_NN plus_CC ampicillin_NN plus_CC clavulanate_NN during_IN the_DT 4th_JJ week_NN worsened_VBD the_DT side_NN effects_NNS ,_, leading_VBG to_TO reinitiation_NN of_IN the_DT former_JJ regimen_NN ._SENT After_IN 6_CD weeks_NNS of_IN intravenous_JJ therapy_NN ,_, treatment_NN was_VBD changed_VBN to_TO oral_JJ levofloxacin_NN and_CC minocycline_NN based_VBN upon_IN susceptibility_NN test_NN results_NNS and_CC accounting_NN for_IN multiple_JJ drug_NN intolerances_NNS ._SENT The_DT patient_NN was_VBD discharged_VBN home_NN with_IN this_DT therapy_NN and_CC since_IN then_RB has_VBZ been_VBN seen_VBN regularly_RB in_IN our_PP$ outpatient_NN clinic_NN ._SENT The_DT leukocyte_NN count_NN in_IN the_DT CSF_NP decreased_VBD ,_, but_CC it_PP remained_VBD mildly_RB elevated_VBN for_IN more_JJR than_IN 10_CD weeks_NNS before_IN falling_VBG to_TO 10/mm3_JJ ._SENT The_DT pathological_JJ findings_NNS in_IN magnetic_JJ resonance_NN imaging_NN of_IN the_DT brain_NN remained_VBD unchanged_JJ ,_, but_CC the_DT neurological_JJ symptoms_NNS have_VBP improved_VBN ._SENT CSF_NP specimens_NNS for_IN bacterial_JJ culture_NN obtained_VBN on_IN readmission_NP were_VBD inoculated_VBN in_IN liquid_JJ media_NNS (_( BHB_NP and_CC the_DT commercially_RB available_JJ VITAL_NP blood_NN culture_NN system_NN [_SYM bioMerieux_NP S.A._NP ,_, Marcy_NP l'Etoile_NP ,_, France_NP ]_SYM for_IN aerobic_JJ and_CC anaerobic_JJ incubation_NN )_) ,_, as_RB well_RB as_IN on_IN BA_NP ,_, CA_NP ,_, and_CC brain_NN heart_NN agar_NN (_( BHA_NP )_) ._SENT Agars_NNS and_CC liquid_JJ media_NNS showed_VBD no_DT signs_NNS of_IN bacterial_JJ growth_NN after_IN 7_CD days_NNS of_IN incubation_NN ._SENT Subcultures_NNS of_IN the_DT aerobic_JJ blood_NN culture_NN medium_NN (_( not_RB detected_VBN as_IN positive_JJ by_IN the_DT automatic_JJ fluorescence_NN readout_NN system_NN )_) on_IN BA_NP ,_, CA_NP ,_, and_CC BHA_NP yielded_VBD yellowish_JJ colonies_NNS after_IN 5_CD days_NNS of_IN incubation_NN at_IN 36C_JJ in_IN an_DT atmosphere_NN enriched_VBN with_IN 5_CD %_NN CO2_NN ,_, whereas_IN there_EX was_VBD no_DT bacterial_JJ growth_NN in_IN subcultures_NNS of_IN the_DT BHB_NP ._SENT Growth_NN was_VBD most_RBS abundant_JJ on_IN CA_NP ;_: the_DT colonies_NNS developed_VBD white_JJ aerial_JJ hyphae_NNS after_IN 3_CD to_TO 4_CD days_NNS of_IN incubation_NN ._SENT On_IN microscopic_JJ examination_NN of_IN BHA_NP ,_, microcolonies_NNS showed_VBD irregular_JJ branching_NN ._SENT Growth_NN of_IN nocardiae_NNS (_( confirmed_VBN by_IN subculture_NN and_CC microscopy_NN )_) was_VBD also_RB found_VBN on_IN Loewenstein-Jensen_NP agar_NN after_IN 2_CD weeks_NNS of_IN incubation_NN ._SENT The_DT Gram-_NP and_CC Ziehl-Neelsen-stained_NP preparations_NNS from_IN single_JJ colonies_NNS showed_VBD mostly_RB gram-positive_JJ branched_VBN rods_NNS and_CC coccoid_JJ fragments_NNS ,_, as_RB well_RB as_IN partially-acid-fast_NN rods_NNS and_CC coccoid_JJ fragments_NNS ,_, respectively_RB ._SENT The_DT morphology_NN of_IN the_DT colonies_NNS and_CC the_DT typical_JJ Gram_NP and_CC acid-fast_JJ stains_NNS led_VBN to_TO the_DT diagnosis_NN of_IN Nocardia_NP species_NNS ._SENT Tests_NNS for_IN basic_JJ biochemical_JJ reactions_NNS ,_, such_JJ as_IN oxidative_JJ and_CC fermentative_JJ glucose_NN use_NN ,_, gelatin_NN liquefaction_NN ,_, nitrate_NN reduction_NN ,_, and_CC urea_NN hydrolysis_NN ,_, were_VBD negative_JJ ._SENT In_IN addition_NN ,_, the_DT isolate_NN showed_VBD remarkable_JJ susceptibility_NN to_TO a_DT wide_JJ range_NN of_IN antimicrobial_JJ agents_NNS (_( disk_NN diffusion_NN test_NN on_IN Mueller-Hinton_NP agar_NN [_SYM data_NNS not_RB shown_VBN ]_SYM )_) ._SENT Subsequent_JJ sequence_NN determination_NN of_IN a_DT 600-bp_JJ fragment_NN amplified_VBN from_IN the_DT 3_CD '_POS end_NN of_IN the_DT 16S_JJ rRNA_NN gene_NN identified_VBD the_DT isolate_NN as_IN Nocardia_NP paucivorans_NNS ._SENT The_DT diagnosis_NN was_VBD confirmed_VBN by_IN the_DT German_JJ national_JJ consultant_NN laboratory_NN for_IN actinomycetes_NNS ._SENT Comparative_JJ in_IN vitro_NN susceptibility_NN testing_NN including_VBG the_DT N._NP paucivorans_NNS type_NN strain_NN (_( DSM_NP 44386T_NP )_) was_VBD performed_VBN on_IN Mueller-Hinton_NP agar_NN at_IN 36C_JJ in_IN an_DT atmosphere_NN enriched_VBN with_IN 5_CD %_NN CO2_NN by_IN using_VBG the_DT Etest_JJ system_NN ,_, and_CC results_NNS were_VBD read_VBN after_IN 24_CD and_CC 48_CD h._NP Strains_NP of_IN Nocardia_NP nova_NN (_( ATCC_NP 33726_CD )_) and_CC Nocardia_NP farcinica_NP (_( ATCC_NP 3308_CD )_) along_IN with_IN previously_RB published_VBN results_NNS of_IN broth_NN dilution_NN testing_NN for_IN these_DT organisms_NNS were_VBD used_VBN as_IN controls_NNS ._SENT The_DT results_NNS from_IN our_PP$ isolate_NN confirmed_VBD those_DT obtained_VBN by_IN disk_NN diffusion_NN testing_NN ._SENT Slightly_RB higher_JJR MICs_NN were_VBD found_VBN for_IN the_DT N._NP paucivorans_NNS type_NN strain_NN ,_, for_IN which_WDT no_DT susceptibility_NN data_NNS have_VBP been_VBN available_JJ ._SENT The_DT results_NNS from_IN the_DT control_NN strains_NNS were_VBD comparable_JJ to_TO those_DT published_VBN previously_RB ._SENT Discussion_NN ._SENT |_SYM The_DT ubiquitous_JJ nocardiae_NNS are_VBP aerobic_JJ actinomycetes_NNS found_VBD worldwide_RB in_IN soil_NN ,_, sand_NN ,_, and_CC house_NN dust_NN ._SENT The_DT organisms_NNS are_VBP characterized_VBN as_IN gram-positive_JJ ,_, partially-acid-fast_NNS branched_VBD rods_NNS that_WDT form_VBP irregular_JJ branching_VBG colonies_NNS on_IN agar_NN ;_: aerial_JJ hyphae_NNS may_MD be_VB present_JJ in_IN some_DT species_NN ._SENT The_DT respiratory_JJ tract_NN and_CC skin_NN are_VBP the_DT sites_NNS of_IN entry_NN in_IN most_JJS cases_NNS of_IN nocardiosis_NN ,_, and_CC nosocomial_JJ outbreaks_NNS of_IN wound_NN infections_NNS have_VBP been_VBN reported_VBN ._SENT The_DT course_NN of_IN the_DT disease_NN may_MD be_VB subclinical_JJ and_CC self-limiting_NN ,_, but_CC chronic_JJ disease_NN can_MD develop_VB ._SENT The_DT nocardiae_NNS can_MD spread_VB from_IN the_DT site_NN of_IN entry_NN to_TO the_DT brain_NN ,_, kidneys_NNS ,_, eyes_NNS ,_, bones_NNS ,_, joints_NNS ,_, and_CC other_JJ organ_NN systems_NNS ._SENT Immunocompromised_JJ hosts_NNS (_( e.g._FW ,_, patients_NNS with_IN AIDS_NP ,_, malignancies_NNS ,_, diabetes_NN ,_, or_CC under_IN immunosuppressive_JJ therapy_NN after_IN transplantation_NN or_CC for_IN rheumatological_JJ disorders_NNS )_) are_VBP more_RBR frequently_RB affected_VBN ,_, but_CC cases_NNS among_IN immunocompetent_JJ patients_NNS have_VBP also_RB been_VBN reported_VBN (_( -_: ,_, ,_, ,_, )_) ._SENT The_DT antibiotics_NNS most_RBS frequently_RB used_VBN are_VBP trimethoprim-sulfamethoxazole_NN or_CC minocycline_NN in_IN localized_JJ or_CC mild_JJ cases_NNS and_CC amikacin_NN ,_, imipenem_NN ,_, or_CC cefotaxime_NN in_IN severe_JJ cases_NNS ,_, such_JJ as_IN disseminated_VBN infection_NN ._SENT Recommendations_NNS for_IN the_DT duration_NN of_IN treatment_NN in_IN cases_NNS of_IN cerebral_JJ nocardiosis_NN vary_VBP from_IN 6_CD to_TO 12_CD months_NNS in_IN immunocompetent_JJ hosts_NNS ,_, and_CC some_DT authors_NNS recommend_VBP even_RB longer_JJR treatment_NN regimens_NNS in_IN immunocompromised_JJ individuals_NNS ._SENT There_EX is_VBZ no_DT standard_JJ method_NN for_IN in_IN vitro_NN susceptibility_NN testing_NN of_IN Nocardia_NP species_NNS ,_, but_CC disk_NN diffusion_NN ,_, Etest_NP ,_, and_CC broth_NN and_CC agar_NN dilution_NN methods_NNS have_VBP been_VBN described_VBN (_( ,_, ,_, ,_, -_: )_) ._SENT While_IN high_JJ rates_NNS of_IN resistance_NN to_TO multiple_JJ classes_NNS of_IN antibiotics_NNS have_VBP been_VBN reported_VBN for_IN various_JJ clinical_JJ and_CC environmental_JJ Nocardia_NP isolates_NNS ,_, data_NNS on_IN N._NP paucivorans_NNS are_VBP not_RB available_JJ ._SENT Here_RB ,_, we_PP report_VBP a_DT case_NN of_IN cerebral_JJ infection_NN with_IN the_DT recently_RB defined_VBN species_NNS N._NP paucivorans_NNS ,_, which_WDT is_VBZ closely_RB related_VBN to_TO the_DT Nocardia_NP asteroides_NNS complex_JJ ._SENT Histologically_RB it_PP was_VBD diagnosed_VBN as_IN a_DT cerebellar_JJ nocardial_JJ abscess_NN ,_, and_CC microbiologically_RB after_IN its_PP$ spread_NN to_TO the_DT meninges_NNS ,_, representing_VBG a_DT rare_JJ manifestation_NN of_IN nocardiosis_NN ._SENT Different_JJ factors_NNS may_MD have_VB contributed_VBN to_TO the_DT failure_NN to_TO cure_VB the_DT disease_NN and_CC the_DT consequent_JJ relapse_NN in_IN this_DT patient_NN despite_IN in_IN vitro_NN susceptibility_NN of_IN the_DT isolate_NN to_TO all_DT drugs_NNS administered_VBN ._SENT Because_IN the_DT specific_JJ immune_JJ response_NN to_TO nocardiae_NNS is_VBZ mainly_RB T-cell_NN mediated_VBD ,_, the_DT patient_NN 's_POS immunosuppression_NN is_VBZ likely_JJ to_TO have_VB played_VBN a_DT role_NN in_IN addition_NN to_TO drug-_NN and_CC pathogen-related_JJ factors_NNS ._SENT These_DT include_VBP the_DT duration_NN of_IN treatment_NN ,_, as_RB well_RB as_IN poor_JJ penetration_NN of_IN minocycline_NN into_IN the_DT CSF_NP and_CC its_PP$ bacteriostatic_JJ mode_NN of_IN action_NN ._SENT Additionally_RB ,_, L-forms_NP of_IN Nocardiae_NP ,_, which_WDT can_MD persist_VB within_IN host_NN tissues_NNS ,_, have_VBP been_VBN described_VBN ._SENT Ours_PP is_VBZ the_DT first_JJ reported_JJ case_NN of_IN N._NP paucivorans_NNS isolated_VBN from_IN the_DT CSF_NP of_IN a_DT patient_NN with_IN intracranial_JJ or_CC intrathecal_JJ manifestation_NN of_IN nocardiosis_NN ._SENT It_PP demonstrates_VBZ that_IN this_DT species_NNS can_MD cause_VB severe_JJ systemic_JJ infections_NNS similar_JJ to_TO those_DT caused_VBN by_IN other_JJ medically_RB important_JJ Nocardia_NP species_NNS ,_, such_JJ as_IN N._NP asteroides_NNS ,_, N._NP farcinica_NP ,_, and_CC N._NP otitidiscaviarum_NN ._SENT The_DT remarkably_RB low_JJ level_NN of_IN antimicrobial_JJ resistance_NN associated_VBN with_IN the_DT few_JJ unique_JJ biochemical_JJ characteristics_NNS of_IN both_CC the_DT isolate_NN reported_VBD here_RB and_CC the_DT type_NN strain_NN of_IN N._NP paucivorans_NP necessitates_VBZ its_PP$ identification_NN by_IN molecular_JJ methods_NNS ._SENT FIG._NN 1_CD ._SENT |_SYM Nocardiae_NP (_( arrow_NN )_) in_IN a_DT Grocott-stained_JJ histological_JJ section_NN of_IN the_DT brain_NN abscess_NN material_NN ._SENT Nocardiae_NP (_( arrow_NN )_) in_IN a_DT Grocott-stained_JJ histological_JJ section_NN of_IN the_DT brain_NN abscess_NN material_NN ._SENT Magnification_NN ,_, x500_NN ._SENT TABLE_NN 1_CD |_SYM MICs_NN of_IN the_DT N._NP paucivorans_NP CSF_NP isolate_NN ,_, the_DT N._NP paucivorans_NNS type_NN strain_NN N._NP nova_NN ,_, and_CC N._NP farcinica_NP as_RB read_VBD by_IN Etest_NP on_IN Mueller-Hinton_NP agar_NN 